| Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, Co. has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency. We show 42 historical shares outstanding datapoints in our coverage of ALXN's shares outstanding history.|
Understanding the changing numbers of ALXN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALXN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALXN by allowing them to research ALXN shares outstanding history
as well as any other stock in our coverage universe.